

Publisher: John Wiley & Sons Inc
E-ISSN: 1532-6535|92|2|235-242
ISSN: 0009-9236
Source: CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.92, Iss.2, 2012-08, pp. : 235-242
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content


Doubt About the Feasibility of Preemptive Genotyping
CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 3, 2013-03 ,pp. :


Response to “Doubt About the Feasibility of Preemptive Genotyping”
CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 3, 2013-03 ,pp. :


Challenges and opportunities of pharmacogenetics in drug development
By March Ruth
Personalized Medicine, Vol. 3, Iss. 2, 2006-05 ,pp. :


Pharmacogenetics of Glucose-Lowering Drug Treatment: A Systematic Review
Molecular Diagnosis & Therapy, Vol. 11, Iss. 5, 2007-01 ,pp. :